|
Study | | Medical condition | Country | FDC arm | Separate pills arm | Duration of follow-up | Adherence assessment method |
|
Eron et al., 2000 [15] | 223 | HIV infection | USA | FCD of lamivudine and zidovudine in combination with a PI | Separate lamivudine, zidovudine, and a PI | 4 months | Self-reported adherence |
|
Sosa et al., 2005 [16] | 236 | HIV infection | USA, Panama, Costa Rica, Puerto Rico | Once daily FDC of abacavir and lamivudine in combination with a PI or NNRTI | Twice daily separate abacavir and lamivudine in combination with a PI or NNRTI | 12 months | Pill count |
|
Geiter et al., 1987 [17] | 538 | Pulmonary tuberculosis | USA | FDC of isoniazid, rifampicin, and pyrazinamide for 2 months followed by FDC of isoniazid and rifampin for 4 months | Separate isoniazid, rifampicin, and pyrazinamide for 2 months followed by separate isoniazid and rifampin for 4 months | 6 months | Self-reported adherence, pill count, and appointment keeping |
|
Su and Perng, 2002 [18] | 105 | Pulmonary tuberculosis | Taiwan | FDC of isoniazid, rifampicin, pyrazinamide and ethambutol for 2 months, followed by FDC of isoniazid and rifampicin for 4 months | Separate isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, followed by separate isoniazid and rifampicin for 4 months | 12 months | Adherence with clinic visits |
|
RCTAI, 1989 [19] | 196 | Pulmonary tuberculosis | India | FDC of isoniazid, rifampicin, and pyrazinamide for 8 weeks followed by FDC of isoniazid and rifampin for 18 weeks | Separate isoniazid, rifampicin, and pyrazinamide for 8 weeks followed by separate of isoniazid and rifampin for 18 weeks | 26 weeks | Home based pill counts |
|
Asplund et al., 1984 [20] | 160 | Hypertension | Sweden | FDC of pindolol and clopamide | Separate pindolol and clopamide | 8 months | Pill count |
|